Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS).
Diamant ThaҫiAndreas PinterMichael SebastianChristian TermeerMichael SticherlingSascha GerdesKnut SchäkelSven WegnerStefanie KrampeHolger BartzChristian RauschFriedemann TautKilian EyerichPublished in: The British journal of dermatology (2024)
In these exploratory analyses, GUS, as a first-line systemic treatment or second-line systemic treatment in FAE nonresponders, was associated with long-term clinical efficacy up to week 100, including a withdrawal period.